Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when he expects the Medicines and Healthcare products Regulatory Agency to publish its decision on the licensing of DCVax-L..

The Medicines and Healthcare Products Regulatory Agency (MHRA) is an executive agency of the Department and regulates medicine, medical devices, and blood components for transfusion in the United Kingdom, with responsibility for ensuring that medicines meet appropriate standards of safety, quality, and efficacy.

Northwest Biotherapeutics has submitted a Marketing Authorization Application (MAA) to the MHRA for DCVax®-L, an immunotherapy for glioblastoma. The MHRA are unable to comment on applications during the process of review, but the MHRA can confirm that this application is not affected by any backlogs.